{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:58:43Z","timestamp":1790384323568,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40120-026-01010-1","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:43:08Z","timestamp":1788176588000},"page":"2491-2508","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Patient Experience of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Post-Diagnosis: Results from an International Survey"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8350-8234","authenticated-orcid":false,"given":"Jonathan D.","family":"Santoro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"deFiebre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Lefelar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayotes","family":"Demakakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Hartigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Periquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaleda","family":"Ahmadyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zara","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Palace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"1010_CR1","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","volume":"22","author":"B Banwell","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023;22:268\u201382.","journal-title":"Lancet Neurol"},{"key":"1010_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1260358","volume":"14","author":"JY Hor","year":"2023","unstructured":"Hor JY, Fujihara K. Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide. Front Neurol. 2023;14:1260358.","journal-title":"Front Neurol"},{"key":"1010_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.885218","volume":"13","author":"E Sechi","year":"2022","unstructured":"Sechi E, Cacciaguerra L, Chen JJ, et al. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management. Front Neurol. 2022;13:885218.","journal-title":"Front Neurol"},{"key":"1010_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4103\/aian.aian_728_24","volume":"28","author":"L Pandit","year":"2025","unstructured":"Pandit L. Challenges in the diagnosis and management of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Ann Indian Acad Neurol. 2025;28:10\u20136.","journal-title":"Ann Indian Acad Neurol"},{"key":"1010_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2025.578781","volume":"410","author":"E Sechi","year":"2026","unstructured":"Sechi E, Gastaldi M, Cortese R, et al. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): practical recommendations for diagnosis and management. J Neuroimmunol. 2026;410:578781.","journal-title":"J Neuroimmunol"},{"key":"1010_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ana.25909","volume":"89","author":"A Cobo-Calvo","year":"2021","unstructured":"Cobo-Calvo A, Ruiz A, Rollot F, et al. Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease. Ann Neurol. 2021;89:30\u201341.","journal-title":"Ann Neurol"},{"key":"1010_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.752557","volume":"12","author":"Y Li","year":"2021","unstructured":"Li Y, Xie H, Zhang J, et al. Clinical and radiological characteristics of children and adults with first-attack myelin oligodendrocyte glycoprotein antibody disease and analysis of risk factors for predicting the severity at disease onset in Central China. Front Immunol. 2021;12:752557.","journal-title":"Front Immunol"},{"key":"1010_CR8","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/acn3.51759","volume":"10","author":"JD Santoro","year":"2023","unstructured":"Santoro JD, Beukelman T, Hemingway C, Hokkanen SRK, Tennigkeit F, Chitnis T. Attack phenotypes and disease course in pediatric MOGAD. Ann Clin Transl Neurol. 2023;10:672\u201385.","journal-title":"Ann Clin Transl Neurol"},{"key":"1010_CR9","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s40120-023-00474-9","volume":"12","author":"JD Santoro","year":"2023","unstructured":"Santoro JD, Gould J, Panahloo Z, Thompson E, Lefelar J, Palace J. Patient pathway to diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): findings from a multinational survey of 204 patients. Neurol Ther. 2023;12:1081\u2013101.","journal-title":"Neurol Ther"},{"key":"1010_CR10","first-page":"205521732412746","volume":"10","author":"Y Said","year":"2024","unstructured":"Said Y, Ladakis DC, Lefelar JM, et al. Quality of life is impaired in myelin oligodendrocyte glycoprotein antibody associated disease. Mult Scler J Exp Transl Clin. 2024;10:20552173241274605.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"1010_CR11","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s40120-025-00770-6","volume":"14","author":"JL Bennett","year":"2025","unstructured":"Bennett JL, Paireddy A, Cox C, et al. Patient experience of myelin oligodendrocyte glycoprotein antibody-associated disease: qualitative patient and clinician interviews informing the development of a conceptual model. Neurol Ther. 2025;14:1569\u201387.","journal-title":"Neurol Ther"},{"key":"1010_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13233-7","volume":"272","author":"F Paul","year":"2025","unstructured":"Paul F, Zappacosta S, Narduzzi S, et al. Management and burden of disease in people with myelin oligodendrocyte glycoprotein antibody-associated disease: data from an international, cross-sectional survey. J Neurol. 2025;272:529.","journal-title":"J Neurol"},{"key":"1010_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/antib13020043","volume":"13","author":"P Gklinos","year":"2024","unstructured":"Gklinos P, Dobson R. Myelin oligodendrocyte glycoprotein-antibody associated disease: an updated review of the clinical spectrum, pathogenetic mechanisms and therapeutic management. Antibodies (Basel). 2024;13:43.","journal-title":"Antibodies (Basel)"},{"key":"1010_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2025.101944","volume":"78","author":"J Andersen","year":"2025","unstructured":"Andersen J, Brilot F. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): insights into pathogenesis and biomarkers of prognosis. Semin Immunol. 2025;78:101944.","journal-title":"Semin Immunol"},{"key":"1010_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-025-06101-z","volume":"184","author":"D Gunes","year":"2025","unstructured":"Gunes D, Karaca M, Durmus A, et al. Challenges in the clinical management of rare diseases and center-based multidisciplinary approach to creating solutions. Eur J Pediatr. 2025;184:281.","journal-title":"Eur J Pediatr"},{"key":"1010_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19116456","volume":"19","author":"J Benito-Lozano","year":"2022","unstructured":"Benito-Lozano J, Arias-Merino G, G\u00f3mez-Mart\u00ednez M, et al. Diagnostic process in rare diseases: determinants associated with diagnostic delay. Int J Environ Res Public Health. 2022;19:6456.","journal-title":"Int J Environ Res Public Health"},{"key":"1010_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03319-2","volume":"19","author":"C Phillips","year":"2024","unstructured":"Phillips C, Parkinson A, Namsrai T, et al. Time to diagnosis for a rare disease: managing medical uncertainty. A qualitative study. Orphanet J Rare Dis. 2024;19:297.","journal-title":"Orphanet J Rare Dis"},{"key":"1010_CR18","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1007\/s00247-025-06342-y","volume":"55","author":"YH Choi","year":"2025","unstructured":"Choi YH, Kim WJ, Lim BC, et al. Neuroimaging spectrum of myelin oligodendrocyte glycoprotein antibody-associated disease with brain involvement: description of various cerebral syndromes. Pediatr Radiol. 2025;55:2115\u201326.","journal-title":"Pediatr Radiol"},{"issue":"7 suppl 1","key":"1010_CR19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000205275","volume":"102","author":"A Patel","year":"2024","unstructured":"Patel A, Martin A, Perkowski K, et al. Burdens of neuromyelitis optica spectrum disorder: real-world perspectives from caregivers (P10-14.002). Neurology. 2024;102(7 suppl 1):3642.","journal-title":"Neurology"},{"key":"1010_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0300777","volume":"19","author":"DC Esiason","year":"2024","unstructured":"Esiason DC, Ciesinski N, Nurse CN, et al. The psychological burden of NMOSD\u2014a mixed method study of patients and caregivers. PLoS ONE. 2024;19:e0300777.","journal-title":"PLoS ONE"},{"key":"1010_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03796-z","volume":"20","author":"B Johnson","year":"2025","unstructured":"Johnson B, Gibson G, Baskerville D, et al. Health-related quality of life and productivity burden for non-professional caregivers of adults with rare diseases: a real-world study. Orphanet J Rare Dis. 2025;20:282.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01010-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01010-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01010-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:02:53Z","timestamp":1790380973000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-01010-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1010"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01010-1","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"7 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jonathan D. Santoro receives compensation through UCB on the topic of MOGAD; he also performs advisory work for TG Therapeutics and Cycle Pharmaceuticals on neuroimmunology topics not inclusive of MOGAD. Gabrielle deFiebre is Executive Director at SRNA. Julia Lefelar is Executive Director and Co-Founder of The MOG Project and a Consultant for UCB. Panayotes Demakakos and Danielle Hartigh are employees of UCB. Magali Periquet was an employee of UCB at the time of the study, and is now an employee of Krystal Biotech Germany GmbH, Berlin. Khaleda Ahmadyar and Zara Morrison were employees of OPEN Health Communications, who were commissioned by UCB to conduct the research, at the time of the study. Khaleda Ahmadyar is now an independent consultant. Zara Morrison is now an employee of Imperial College London. Jacqueline Palace has received support for scientific meetings and honoraria for advisory work from Merck Serono, Novartis, Chugai, Alexion, Roche, MedImmune, Argenx, Sanofi, UCB, Mitsubishi, Amplo Biotechnology, and Janssen; has received grants from Alexion, Roche, Medimmune, and Amplo Biotechnology; holds patent ref. P37347WO and license agreement with numares multimarker MS diagnostics; has shares in AstraZeneca; and acknowledges partial funding by highly specialized services of NHS England.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional review board of the Children\u2019s Hospital Los Angeles and the University of Southern California (reference number CHLA-21-01922). The study was conducted in accordance with the 1964 Declaration of Helsinki and its later amendments. All participants gave informed consent, including consent for their anonymized, aggregated data to be shared as research findings.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}